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Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm) are
Tier-1 Select Agents that cause melioidosis and glanders, respec-
tively. These are highly lethal human infections with limited ther-
apeutic options. Intercellular spread is a hallmark of Burkholderia
pathogenesis, and its prominent ties to virulence make it an at-
tractive therapeutic target. We developed a high-throughput cell-
based phenotypic assay and screened ∼220,000 small molecules
for their ability to disrupt intercellular spread by Burkholderia
thailandensis, a closely related BSL-2 surrogate. We identified
268 hits, and cross-species validation found 32 hits that also dis-
rupt intercellular spread by Bp and/or Bm. Among these were a
fluoroquinolone analog, which we named burkfloxacin (BFX),
which potently inhibits growth of intracellular Burkholderia, and
flucytosine (5-FC), an FDA-approved antifungal drug. We found
that 5-FC blocks the intracellular life cycle at the point of type VI
secretion system 5 (T6SS-5)-mediated cell–cell spread. Bacterial
conversion of 5-FC to 5-fluorouracil and subsequently to fluorouridine
monophosphate is required for potent and selective activity against
intracellular Burkholderia. In a murine model of fulminant re-
spiratory melioidosis, treatment with BFX or 5-FC was significantly
more effective than ceftazidime, the current antibiotic of choice,
for improving survival and decreasing bacterial counts in major
organs. Our results demonstrate the utility of cell-based pheno-
typic screening for Select Agent drug discovery and warrant
the advancement of BFX and 5-FC as candidate therapeutics for
melioidosis in humans.
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Burkholderia pseudomallei (Bp) and Burkholderia mallei (Bm),the etiologic agents of melioidosis and glanders, respectively,
are highly infectious gram-negative bacteria for which limited
therapeutic options exist. Bp normally inhabits the rhizosphere
(1, 2) and can be acquired by humans and other mammals via
inhalation, ingestion, or percutaneous inoculation (3, 4). Indi-
viduals regularly exposed to soil and water in endemic areas are
disproportionately affected. The severity of disease varies from
chronic infection mimicking tuberculosis to acute, florid sepsis.
Clinical management is complicated by antibiotic resistance
(5–8), and mortality rates are high despite appropriate diagnosis
and treatment (9). Bm is an evolutionary descendent of Bp (10)
with a restricted host range that primarily includes solid-
ungulates, although it can also cause life-threatening zoonotic
infections in humans (11, 12). In light of their low infectious
doses, high lethality, extensive antibiotic resistance, and the
lack of protective vaccines, Bm and Bp are classified as Tier 1
Select Agent pathogens. Concern over malign release against
civilian or military targets is heightened in light of their historical
use as bioweapons (13, 14). A third, less-pathogenic member of
the B. pseudomallei complex (Bp complex), B. thailandensis (Bt),
shares highly conserved virulence mechanisms with its patho-
genic relatives, making it a useful BSL-2 surrogate (15–17).
Although the true global burden of melioidosis is unknown,
recent estimates suggest that Bp is endemic in at least 79 coun-
tries and is responsible for 165,000 annual human infections, of
which 54% are fatal (18). Highly endemic areas include north-
east Thailand, where Bp is the leading cause of community-
acquired bacteremia, and the Northern Territory of Australia,
where Bp is the most common cause of fatal community-acquired
bacteremic pneumonia (19–21). The current treatment regimen
for melioidosis consists of an initial parenteral phase lasting 10 to
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14 d aimed at preventing death, followed by an oral eradication
phase lasting >3 mo aimed at preventing relapse. Ceftazidime
and carbapenems are the mainstays for acute phase therapy,
while trimethoprim-sulfamethoxazole (cotrimoxazole) or amoxicillin-
clavulanic acid (coamoxiclav) are the choices for eradication
phase therapy (4, 22). The efficacy of current treatment regimens
is limited, however, by intrinsic and acquired antibiotic resistance
(8, 23–26). The consequences of naturally occurring disease, the
potential for nefarious use, the lack of effective vaccines, and
drug resistance make the development of new countermeasures
a high priority.
Bp complex species can parasitize mammalian cells, and their
ability to replicate intracellularly and spread from cell to cell is
an essential virulence trait (4). Following entry by phagocytosis
or invasion, bacteria escape from endocytic vesicles using the Bsa
type III secretion system (T3SSBsa) (27, 28) (Fig. 1). Bacteria
then multiply in the cytoplasm, move through the cytosol by
BimA-mediated actin polymerization (29), and spread to
neighboring cells by a process involving membrane fusion (28,
30), creating a portal for direct passage of bacteria into neigh-
boring cytosolic compartments (31). Membrane fusion requires
the activity of type VI secretion system 5 (T6SS-5), 1 of 6 T6SSs
encoded in Bp complex genomes (31–33), and multiple cell fu-
sion events result in the formation of large multinucleate cells
(MNCs) which eventually lyse to form lesions (i.e., plaques) on
cell monolayers (28).
Host cell fusion by Bp complex species differs significantly
from multinucleated giant cell (MGC) formation observed in
mycobacterial infections or other granulomatous diseases. In
these settings, MGCs develop by cytokine-mediated activation of
a fusion program that is intrinsic to monocytes and macrophages
and can be reproduced in vitro in the absence of bacteria by the
addition of cytokines alone (34). In contrast, cell fusion by Bp, Bt,
and Bm results from the activity of a bacterial virulence de-
terminant, T6SS-5, a contractile nanotube evolutionarily related
to phage tails that is embedded in the cell envelope and fires
outward (35–39). According to the current model (Fig. 1), en-
counters between intracellular Burkholderia and the plasma
membrane lead to T6SS-5 contraction, firing of a bacterially
encoded fusogenic protein (VgrG5) across the bacterial enve-
lope and through the plasma membranes of the infected cell and
an adjacent cell, causing local deformation and merging of op-
posing bilayers (28, 31). Burkholderia are able to fuse a wide
range of cell types in vitro, including epithelial cells, endothelial
cells, fibroblasts, monocytes, and macrophages (40), and fusion
ability correlates with virulence by Bp and Bm (32, 41–43).
Target-based screening campaigns against gram-negative
bacteria have been largely unsuccessful due to the inability of
many small molecules to penetrate the bacterial outer membrane
(44–46). Furthermore, prior efforts to develop therapeutics
against Burkholderia have shown that despite having activity
in vitro, compounds are often ineffective in vivo due to the ability
of Bp and Bm to survive and replicate intracellularly (47). With
these limitations in mind, we developed a cell-based phenotypic
screen for small-molecule inhibitors of intracellular Burkholderia
that are actively replicating within and spreading between
mammalian cells. Our high-throughput (HT) assay comprehen-
sively assesses the entire Burkholderia intercellular life cycle,
including the critical step of cell–cell fusion. We screened
∼220,000 small molecules for their ability to disrupt intercellular
spread by Bt and validated positive hits using the BSL-3 patho-
gens Bp and Bm. This strategy identified 32 compounds that
disrupt the intracellular life cycle of Bp and/or Bm. We describe
the mechanistic characterization of 2 of our most potent inhibi-
tors, which hold promise as therapeutic countermeasures against
melioidosis.
Results
A High-Throughput Phenotypic Screen Identifies Small-Molecule
Inhibitors of Burkholderia Intercellular Spread. The cell fusion as-
say shown in Fig. 2A was adapted for high-throughput screening
by seeding eGFP-expressing HEK293 cells into 384-well plates
pinned with a library of small molecules, infecting cells with
Burkholderia, and imaging 18 to 22 h later using laser scanning
cytometry to assess the relative abundance and size of plaques
(Fig. 2 B and C). Given that the readout results from cell fusion
mediated by intracellular bacteria, the assay is capable of iden-
tifying compounds that inhibit any step of the intracellular in-
fection pathway, have relatively low toxicity against mammalian
cells, and are capable of penetrating both the host cell plasma
membrane and the gram-negative cell envelope.
A curated small-molecule library was screened for inhibitory
activity against intracellular Bt strain E264 utilizing the facilities
of the University of California, Los Angeles (UCLA), Molecular
Screening Shared Resource (MSSR). Fig. 2C shows a pilot
screen using an FDA-approved sublibrary of 1,120 compounds,
demonstrating the ability to identify known (trimethoprim) as
well as new inhibitors. Screening efforts were then scaled to
accommodate >220,000 compounds. Over the course of the
screen, control wells yielded negligible false-positive (0%) and
false-negative (0.0091%) hit rates. An initial set of 268 com-
pounds was found to inhibit plaque formation by Bt E264,
yielding a conservative primary hit rate of 0.0012. Validation was
conducted using Bt E264, Bp 1026b (Thai clinical isolate), and
Bm 23344 (human isolate), resulting in 114 (43%) validated
compounds that were binned according to species activity (Fig.
2D). Of these, 4 compounds, including 3 known antibiotics and 1
molecule which we named burkfloxacin (BFX), were found to
consistently inhibit plaque formation by all 3 organisms. Seven
compounds, including 4 known antibiotics, inhibited plaque
formation by Bm and Bp, and 4 compounds were specific for Bm
only, including monensin and the antimalarial drug artemisinin.
Flucytosine (5-fluorocytosine, 5-FC), an FDA-approved anti-
mycotic, was identified among the hits with activity against
Bp and Bt but not Bm. Following validation of activity against
intracellular Burkholderia, cytotoxicity was assessed in HEK293
cells using an ATP-depletion cell viability assay. Both BFX and
5-FC had no apparent effect on cell viability at concentrations
10-fold higher than the IC100 (SI Appendix, Table S1) and were
prioritized for follow-up studies.
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Fig. 1. Intracellular life cycle of B. pseudomallei complex species, showing
points of inhibition by 2 newly discovered small-molecule inhibitors, burk-
floxacin (BFX) and flucytosine (5-FC). Diagram of the Burkholderia in-
tercellular life cycle, illustrating the ability to invade mammalian cells,
escape from endosomes/phagosomes, locomote in the cytosol by polymer-
izing host actin, replicate intracellularly, and fuse host cell membranes by a
T6SS-5–dependent mechanism (31). Two priority compounds, BFX and 5-FC,
were found to inhibit intracellular replication and cell fusion, respectively.
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BFX Potently Inhibits Growth of Intracellular Burkholderia.BFX (Fig.
3A) is a morpholinated fluoroquinolone analog originally syn-
thesized in 1980 by Koga et al. (48). In this and a subsequent
study (49), it was found to have in vitro activity against a limited
panel of bacterial species and a favorable toxicity profile. We
confirmed that BFX is active against other gram-negative or-
ganisms in vitro, showing similar potency to the widely used
fluoroquinolone, ciprofloxacin (Cip), against Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 (SI
Appendix, Table S2). We also confirmed that BFX, like Cip,
functions as a canonical fluoroquinolone by demonstrating its
ability to inhibit the negative DNA supercoiling activity of E. coli
DNA gyrase (Fig. 3B).
As shown in Fig. 3C, BFX results in near-complete inhibition
of plaque formation by Bt and Bp at a concentration of 0.5 μM.
In the intracellular growth experiment in Fig. 3D, bacteria rep-
licate exponentially in the absence of drug until ∼16 h, when
membrane damage accumulates to an extent sufficient to expose
intracellular bacteria to bactericidal levels of kanamycin present
in the media. In contrast, intracellular growth is ablated fol-
lowing treatment with BFX. When compared to Cip present at
the same concentration (1.0 μm), BFX resulted in a 7-fold re-
duction in colony forming units (CFU) at the point of maximal
intracellular growth (16 h, Fig. 3E), and in plaque assays, BFX
inhibited cell–cell spread at an 8-fold lower concentration com-
pared to Cip (SI Appendix, Fig. S1). Interestingly, significantly
higher doses of BFX (5 μM) were needed to inhibit growth in
laboratory medium (Fig. 3F), compared to intracellular growth
in HEK293 cells (Fig. 3D), suggesting that BFX accumulation
may occur inside mammalian cells as observed with certain other
fluoroquinolones (50).
The FDA-Approved Antifungal, 5-FC, Inhibits Intercellular Spread at
the Step of Cell–Cell Fusion. Our screen also identified 5-FC (Fig.
4A), an FDA-approved antimycotic, as an inhibitor of plaque
formation by Bt and Bp. Flucytosine is a fluorinated cyto-
sine analog that serves as a first-line therapy for serious fungal
infections, such as cryptococcal meningitis (51), and is included
in the World Health Organization’s List of Essential Medicines
(52). In light of its established efficacy as an antifungal agent,
we investigated the mechanism of 5-FC activity as an inhibitor
of Burkholderia cell–cell spread. As shown in Fig. 4B, 5-FC in-
hibits plaque formation by Bt and Bp in a dose-dependent
fashion, as indicated by a decrease in both plaque numbers
and size (also see Fig. 2C). Flucytosine does not affect bacterial
growth in laboratory medium at a concentration that nearly
eliminates plaque formation (Fig. 4C). Similarly, 5-FC does not
prevent growth of intracellular bacteria at concentrations that
inhibit plaque formation, although a decrease and delay in
attaining peak bacterial numbers is observed (Fig. 4D). Plaque
formation is inhibited whether 5-FC is added to cells before or
after bacterial infection (Fig. 4E), indicating an effect on a late
intracellular life cycle event. This contrasts with 2 other com-
pounds identified in our screen, Invasion Inhibitor-1 (II-1) and
Invasion Inhibitor-2 (II-2), which show strong inhibition
of cell–cell spread when added prior to infection but minimal
activity when added after infection, as expected for inhibitors of
invasion (Fig. 4E). For 5-FC, the proportion of cytosolic bac-
teria associated with actin tails is equivalent in treated and
untreated cells (Fig. 4F). Importantly, in comparison to the
wild-type (WT) strain (Fig. 4D), peak intracellular growth levels
of a fusion-defective ΔvgrG5 mutant (31) were not significantly
affected by 5-FC (Fig. 4G), although we did observe a delay that
was similar to that seen with the WT strain (Fig. 4D). Since cell
fusion allows expansion of the Burkholderia replicative niche and
facilitates intracellular replication, the lack of a difference in
peak numbers for the ΔvgrG5 mutant with or without 5-FC, to-
gether with time of addition data (Fig. 4E) and observations of
actin polymerization by cytosolic bacteria (Fig. 4F), support the
hypothesis that 5-FC inhibits a late-stage event in the intracellular
life cycle that is required for cell fusion.
To further explore the inhibitory mechanism, we investigated
the effects of 5-FC on the expression of virulence loci known
to facilitate intracellular survival and cell–cell spread (53).
Quantitative RT-PCR measurements of transcripts from genes
involved in virulence regulation (virG and bsaN), endosome
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Fig. 2. High-throughput screening for small-molecule
inhibitors of Burkholderia intercellular spread. (A) Cell
fusion assay with example well images. HEK293-GFP
cell monolayers were infected at a multiplicity of in-
fection of 0.01, treated with 125 μg/mL kanamycin
after 1 h to prevent extracellular growth, and in-
cubated for 20 h. Burkholderia-driven membrane fu-
sion leads to multinucleate cells that eventually lyse to
form plaques. (B) Schematic of the high-throughput
phenotypic small-molecule screen. The 384-well
plates containing cell culture media were pinned
with small molecules dissolved in DMSO for a final
concentration of 5 μM. Cells were then seeded onto
plates (35,000 per well), incubated for 24 h, then
subjected to cell fusion assays and evaluated for plaque
formation. Red stars represent compounds that
cause complete inhibition, purple pentagrams indicate
partial inhibition (small plaque phenotype as shown or
reduced number of plaques), and yellow squares rep-
resent no inhibitory effect. (C) Example 384-well plate
image from screening of an FDA-approved drug li-
brary (Prestwick) at 5 μM concentration, with Bt E264.
(Lower) The enlarged image of a positive control well
(DMSO-treated and infected), negative control well
(uninfected), and wells containing trimethoprim and
flucytosine (5-FC). (D) A proportional Venn diagram
showing the number of small molecules that reproducibly inhibited intercellular spread by Bt, Bp, and/or Bm. Of the 268 primary hits originally identified during
high-throughput screening against Bt, 92 reproducibly inhibited Bt intercellular spread, and 32 reproducibly inhibited intercellular spread by Bp and/or Bm. Known
drugs identified in the screen are listed by category in the Venn diagram and include numerous FDA-approved antibiotics, as well as the antimalarial artemisinin,
which showed activity against Bm. Hit validation experiments with Bt, Bp, and Bm were performed in 384-well plate format with at least 3 technical and 2 bi-
ological replicates. MNC, multinucleate cell; HTS, high-throughput screen; PI, postinfection.
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escape (bsaM and bopE), intracellular motility (fliC2 and bimA),
or T6SS-5–dependent membrane fusion (clpV5 and vgrG5) were
performed on RNA isolated from HEK293 cells infected with Bt
E264 in the presence or absence of 5-FC. With treatment, we
found a modest (≤4-fold) and variable reduction in the expres-
sion of virG, bsaM, bimA, and vgrG5 and an even smaller effect
on bsaN, bopE, flic2, or clpV5 (Fig. 4H). This seemed unlikely to
account for the near-complete elimination of plaque formation
observed with 5-FC at the same concentration (25 μm), and more
likely due to secondary growth effects resulting from the lack of
efficient cell fusion. Finally, we examined whether 5-FC has an
inhibitory effect on the functionality of T6SS-5 in vitro using a
previously established assay (31) involving strains engineered to
constitutively express VirAG, a 2-component regulatory system
that normally activates T6SS-5 gene expression in the mamma-
lian cell cytosol (54). On Western blots, we observed a significant
decrease in the quantity of Hcp5, the T6SS-5 intertubule subunit
protein, secreted into culture supernatants by Bt and Bp fol-
lowing 5-FC treatment (Fig. 4I). In contrast, expression of Hcp5
was not noticeably affected by 5-FC, as demonstrated by equiv-
alent signal intensities in the cell pellet fractions of treated vs.
untreated controls (Fig. 4I). These results are consistent with an
inhibitory effect of 5-FC on the assembly or secretion activity of
T6SS-5 and a consequent decrease in the efficiency of cell–
cell spread.
Flucytosine Is a Prodrug That Requires Conversion to 5-Fluorouracil
and Fluorouridine Monophosphate. The antifungal activity of 5-FC
against Cryptococcus neoformans and other fungal pathogens is
due to the cytotoxicity of its metabolic products, making it a
prodrug (51, 55). As summarized in Fig. 5A, following uptake by
cytosine permease (CodB) and conversion to 5-fluorouracil (5-
FU) by cytosine deaminase (CodA), 5-FC metabolism bifur-
cates into 2 pathways which ultimately result in antifungal ac-
tivity via inhibition of RNA and DNA synthesis. Orthologous
enzymes and pathways are encoded by Bp complex species (Fig.
5A); however, bacterial growth in vitro is unaffected by 5-FC at
concentrations that suppress Hcp5 secretion under identical
growth conditions (Fig. 4 C and I) and abolish plaque formation
by intracellular organisms (Fig. 4B). Although the reason for the
lack of a primary effect on bacterial growth is presently un-
known, it nonetheless implies a unique mechanism for the in-
hibitory activity of 5-FC. To explore this, we examined the roles
of key metabolic enzymes and products in the ability of 5-FC to
inhibit cell–cell spread.
Pathway 1 (Fig. 5A) is involved in the synthesis of pyrimidine
nucleotide triphosphates. We found that 25 μM 5-FU, like 5-FC,
abolished plaque formation (Fig. 5B). Fluorouridine (FUR), an
intermediate between 5-FU and fluorouridine monophosphate
(FUMP), was minimally inhibitory at 25 μM but fully inhibitory
at 50 μM, suggesting a role for pathway 1. This is consistent with
a lack of inhibition by fluorodeoxyuridine (FUdR), a pathway 2
intermediate, at concentrations up to 50 μM. We next investi-
gated metabolic genes for critical roles in the activity of 5-FC
(Fig. 5C), taking advantage of the availability of an arrayed li-
brary of transposon insertion mutants in Bt (56). Mutations in
genes encoding cytosine deaminase (codA::TnT23) or uracil
phosphoribosyltransferase (upp::TnT23) conferred partial or
complete resistance to 5-FC, respectively, while mutants defective
in thymidine phosphorylase (TP, deoA::TnT23) or ribonucleotide
reductase (RR, Bth_II1936::TnT23) remained susceptible. The
partial sensitivity of the codA::TnT23 strain could be due to
residual activity of the mutant enzyme since the transposon
insertion is positioned downstream from the active site of the
multidomain aminohydrolase (56). Together, these observa-
tions suggest that pathway 2 metabolites, FUdR and FdUMP,
are not required for inhibition, whereas metabolic conversion
to pathway 1 intermediates 5-FU followed by FUMP is critical
for the prodrug activity of 5-FC. FUMP or a downstream me-
tabolite, therefore, are the likely inhibitors of T6SS-5-dependent
intercellular spread.
Chemical Mutagenesis Screen for 5-FC Resistance Yields Mutations
That Accelerate Cell–Cell Spread. To gain further insight into the
inhibitory mechanism of 5-FC, we performed a forward genetic
screen to identify mutations leading to resistance. WT Bt was
treated with the DNA alkylating agent ethyl methanesulfonate
(EMS). Pooled mutagenized bacteria were then used to infect
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Fig. 3. Identification of a fluoroquinolone, BFX, as a potent inhibitor of
Burkholderia intracellular replication. (A) Chemical structure of BFX (1-ethyl-
6-fluoro-7-(4-morpholinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid). (B)
BFX inhibited the negative supercoiling activity of E. coli DNA gyrase, simi-
larly to Cip. RC, relaxed circular; SC, supercoiled. (C) Plaque forming effi-
ciency of Bt E264 and Bp 1026b at varying concentrations of BFX. BFX
treatment resulted in near-complete inhibition of intercellular spread by Bt
E264 and Bp 1026b at a concentration of 0.5 μM. Plaque forming efficiency
was assessed by the number of plaque forming units (PFU) per CFU in con-
fluent HEK293 cell monolayers 16 h after infection with a multiplicity of
infection (MOI) of 4 × 10−4 (*P < 0.001). (D) BFX inhibited intracellular
replication of Bt at a concentration of 0.5 μM. Intracellular bacterial counts
were significantly lower in BFX-treated cells compared to DMSO-treated cells
at 12, 16, and 20 h after infection (*P < 0.05). Intracellular CFUs were de-
termined by treating confluent cell monolayers with 0.5 μM BFX or DMSO,
infecting 1 h later with Bt at an MOI of 1, adding Km 1 mg/mL 1 h after
infection to kill extracellular bacteria, then lysing monolayers and plating
dilutions at predetermined time points (27, 29). (E) At a concentration of
1 μM, 7-fold fewer CFU were recovered from BFX-treated cells vs. Cip-treated
cells at maximal intracellular growth (16 h postinfection) (*P < 0.05). In-
tracellular CFUs were enumerated by infecting monolayers as described
above using an MOI of 1.0. At 16 h postinfection, cells were lysed, and di-
lutions were plated for CFU determinations. (F) BFX did not inhibit in vitro
growth of Bt in LB-NS at a concentration that robustly inhibits intracellular
replication (0.5 μM), but inhibition was observed at a 10-fold higher con-
centration (5 μM) (*P < 0.001). C–F show the mean of at least 3 technical
replicates, with all error bars representing the SD.
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cells in the presence of 25 μM 5-FU (Fig. 6A). The use of 5-FU,
instead of 5-FC, eliminated selection for mutations in the CodB
transporter or the CodA aminohydrolase. MNCs formed by
mutagenized bacteria were isolated 16 h postinfection, lysed with
detergent, and plated on L-agar for isolation of individual
bacterial clones. Resistant phenotypes were validated by plaque
assays in the presence of 5-FU. In total, ∼6 million chemical
mutants containing an average of 8 SNPs per genome were assessed
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indicates constitutive expression of VirAG, the 2-component sensor-regulator that controls expression of T6SS-5, on a chromosomally integrated expression
construct. As T6SS-5 is normally only expressed in the host cytosol (53, 54), constitutive VirAG expression activates T6SS-5 transcription in vitro, allowing
measurements of secretion activity.
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(SI Appendix, Materials and Methods), and 20 demonstrated
reproducible resistance to 5-FU. As detected by PCR amplicon
sequencing, 12 of these resistant mutants had a single missense
mutation at 1 of 10 different sites in upp, and 1 contained a
nonsense mutation, validating our results with the upp::TnT23 in-
sertion mutant (Fig. 5C). No mutations were identified in genes
encoding downstream metabolic enzymes PyrH/PyrR or Ndk. The
remaining resistant mutants were subjected to whole genome se-
quencing (WGS) along with the parental WT strain. Since all
genomes analyzed contained multiple chemically induced muta-
tions, we searched for genomic regions in which SNPs were
identified in more than 1 resistant mutant. Accordingly, 2 regions
with clustered SNPs were found (Fig. 6B), one containing a pair of
regulatory genes which we named Intercellular spread regulators
A and B (isrA and isrB) and another that encodes an array of
biosynthetic genes (thaP, thaO, and adjacent loci) that produce
thailandamide, a polyketide antibiotic that inhibits fatty acid bio-
synthesis by targeting acetyl-coA carboxylase (AccA) (57, 58).
SNP 1 (Fig. 6B) is located on chromosome II, 219 bp upstream
of the isrA coding sequence (CDS) within a region predicted to
encode the isrA promoter, and SNP 2 lies 80 bp upstream of a
small, divergently expressed gene of unknown function (Bth_II1096).
isrA encodes a predicted 28-kDa 2-component response regulator
with a winged helix–turn–helix (HTH) DNA-binding domain.
Although no apparent sensor gene is located nearby, directly up-
stream is a second orphan response regulator locus, isrB, that
encodes a predicted DNA binding protein with a LuxR-type HTH
domain. The availability of TnT23 insertions in isrA and isrB
allowed us to assess their roles in susceptibility to 5-FC. In both
cases, partial resistance was observed (Fig. 6C), with plaques that
were uniformly smaller than the upp::TnT23 metabolic mutant yet
similar to those observed with the original SNP-containing strains.
Also located on chromosome II, SNP 3 is a synonymous substi-
tution that falls in the thaO coding sequence, which encodes a
polyketide synthase required for thailandamide biosynthesis, and
SNP 4 results in a Glu to Lys substitution in ThaP, an adjacent
polyketide synthase. Although the significance of the synonymous
substitution associated with SNP3 was not immediately apparent, the
presence of 2 independent SNPs in the thailandamide biosynthetic
gene cluster prompted further examination. Indeed, using a
thaP::TnT8 mutant, we observed partial resistance to 5-FC in
plaque assays, similar to that seen with isrA and isrB mutant
strains (Fig. 6C).
To our initial surprise, the isrA and thaP insertion mutants
each displayed the striking phenotype of accelerated plaque de-
velopment in the absence of 5-FC (Fig. 6D). For the isrA::TnT23
strain, hyper-plaque formation correlated with increased secretion
of Hcp5, while the thaP::TnT8 mutant showed variable secretion
activity. In either case, we propose that factors that normally limit
the efficiency of cell–cell spread were inactivated by mutations in
chemically mutagenized cells or in independently selected trans-
poson mutants, allowing intracellular Burkholderia to partially
overcome concentrations of 5-FC that would otherwise abrogate
cell–cell spread. The potential basis for the unexpectedly similar
phenotypes of mutations in isrA and thaP and the broader impli-
cations of pathways that confer resistance to 5-FC prodrug are
considered below (Discussion).
BFX and 5-FC Are Efficacious in a Murine Model of Fulminant Melioidosis.
Given the effectiveness of BFX and 5-FC at inhibiting Burkholderia
cell–cell spread, we evaluated their therapeutic efficacy using a
mouse model of acute fulminant melioidosis (59). BALB/c mice
were infected intranasally with 4,500 CFU of Bp 1026b, and BFX
(10 mg/kg/day) or 5-FC (100 mg/kg/day) was administered intra-
peritoneally twice daily, with the first doses given 5 h after infection.
Outcomes were compared to animals that were administered pla-
cebo (PBS + 20% DMSO) or ceftazidime (130 mg/kg/day), the
current antibiotic of choice for treating acute melioidosis. All
animals in the placebo group succumbed to infection within 3 d, and
all ceftazidime-treated animals succumbed by 5 d postinfection. In
contrast, all (100%) of mice receiving BFX and 3/8 (36.7%) mice
treated with 5-FC survived 5 d postinfection (P < 0.001) (Fig. 7A).
Moreover, 5/8 (63%) BFX-treated and 1/8 (12%) 5-FC–treated
mice survived for the duration of the study (10 d). Survival rates
were inversely correlated with bacterial loads in major organs, as
numbers of bacteria in the lungs, livers, and spleens of BFX-treated
mice were decreased relative to placebo and ceftazidime-treated
controls at 48 h postinfection (Fig. 7B). Bacterial loads were
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monophosphate (FUMP). (A) Diagram of 5-FC me-
tabolism in Burkholderia (74) based on the presence
of gene products homologous to those responsible
for metabolic conversion of 5-FC in fungi (55).
Flucytosine is metabolized by the pyrimidine salvage
pathway. The pathway bifurcates into pathways 1 and
2, which provide nucleotide triphosphate (NTP) and
dNTP anabolism and ultimately affect RNA and DNA
synthesis, respectively. CodA, cytosine deaminase;
CodB, cytosine permease; Ndk, nucleoside diphosphate
kinase; PyrH, uridylate kinase; PyrR, bifunctional pyr
mRNA-binding protein/uracil phosphoribosyltransferase;
RNAP, RNA polymerase; RR, ribonucleotide reductase;
SurE, 5′/3′-nucleotidase; TK, thymidine kinase; TP, thy-
midine phosphorylase (DeoA); TS, thymidylate synthase;
UK, uridine kinase; UP, uracil phosphorylase; UPP, uracil
phosphoribosyltransferase. (B) Plaque forming efficiency
of Bt E264 in the presence of 5-FC and its downstream
metabolites. Intercellular spread was inhibited by 5-FC;
5-FU; and, at high concentrations, FUR but not by FUdR
(*P < 0.05). Plaque forming efficiency was assessed by
measuring the number of plaque forming units (PFU)
per CFU in confluent HEK293 cell monolayers 16 h after
infection with a multiplicity of infection of 4 × 10−4. (C)
Insertion of transposon TnT23 (56) into codA or upp, but not deoA (encodes TP) or BTH_II1936 (encodes RR), resulted in resistance to 5-FC at 25 μM, in-
dicating that conversion of 5-FC to 5-FU, and then to FUMP, is essential for the inhibitory effect on Burkholderia. Statistical comparisons are for plaque
forming efficiency in the DMSO-treated condition vs. the 5-FC treated condition (**P < 0.01, *P < 0.05, and n.s. = not significant, P > 0.05). Shown are the
mean and SD of at least 3 technical replicates.
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also decreased, although to a lesser extent, in 5-FC–treated
mice. Interestingly, the majority of surviving mice treated with 5-FC
or BFX showed low or undetectable bacterial loads at 10 d in liver
and spleen compared to lung tissue, suggesting that dissemination
from the lung to these organs might portend a poor outcome (SI
Appendix, Fig. S2). Histopathology of pulmonary, hepatic, and
splenic tissue from mice killed 48 h after infection revealed signif-
icantly reduced inflammation in 5-FC–treated mice relative to PBS-
treated and minimal inflammation in organs of BFX-treated mice
(Fig. 7C). In summary, BFX and 5-FC demonstrate superiority to
ceftazidime in a preclinical model of fulminant melioidosis.
Discussion
The goal of this study was to identify small-molecule inhibitors of
the Burkholderia intercellular life cycle and to evaluate their
therapeutic efficacy. Our cell-based phenotypic screen success-
fully identified inhibitors of intercellular spread by Bt, Bp, and
Bm. We determined the mechanism of action of 1 highly potent
molecule, BFX, as inhibition of DNA gyrase and link the effect
of 5-FC to inhibition of cell–cell spread, most likely at the point
of T6SS-5–mediated membrane fusion.
The intracellular and in vivo efficacy of BFX is intriguing given
that fluoroquinolones have not generally been found effective
for the treatment of melioidosis in animal models or human
clinical trials (22). In contrast, our findings argue that BFX holds
promise as a countermeasure against Bp and other pathogens. In
comparison to ciprofloxacin, significantly increased potency of
BFX was observed during intracellular but not extracellular
growth, suggesting an ability to achieve higher concentrations of
active compound in mammalian cells. If true, further study is
warranted to determine if this is due to enhanced membrane
permeability, a lower isoelectric point and increased activity in
acidic compartments such as the phagolysosome (60, 61), or
some other mechanism. A comprehensive assessment of BFX’s
spectrum of activity, particularly against other intracellular
pathogens such as Shigella and Salmonella, may be informative
and clinically relevant in this regard. In Burkholderia and other
gram-negative bacteria, efflux pumps that actively export anti-
biotics across the bacterial cell envelope are a primary mecha-
nism of fluoroquinolone resistance (26, 62, 63). Thus, it will be of
interest to determine if the enhanced relative potency of BFX
against intracellular Burkholderia provides a means to overcome
efflux-mediated resistance to an extent that improves clinical
outcomes (8, 64).
Our observation that 5-FC provided a significant survival
benefit in a preclinical model of fulminant disease provides a
compelling argument for evaluating the potential to repurpose
this antifungal as an adjunctive therapy for melioidosis (65). As
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SNPs in resistant chemical mutants. SNP 1 is located 219 bp upstream of isrA in a potential promoter region; SNP 2 lies in an intergenic region, 80 bp upstream
of the coding sequence of an adjacent hypothetical protein Bth_II0196 within a potential stem-loop sequence of unknown function; SNP 3 creates a syn-
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also resulted in partial resistance as shown in standard plaque assays with 25 μm 5-FC. A TnT23 insertion in upp, for comparison, resulted in more robust
resistance (*P < 0.05). Shown are the mean and SD of at least 3 technical replicates. (D) isrA and thaP mutants displayed accelerated plaque formation in the
absence of 5-FC. (E) The isrA mutant carrying a plasmid expressing VirG (isrA::TnT23 + pvirG) had consistently increased Hcp secretion (supernatant [s]) but
similar Hcp expression (pellet [p]), relative to WT with pvirG (*P < 0.01). virG was expressed in trans on a replicating plasmid to activate T6SS-5 expression
in vitro, allowing assessment of its secretion activity. The thaPmutant (thaP::TnT8 + pvirG) displayed variable levels of Hcp secretion that were not statistically
different from WT (n.s., P > 0.05). The quantity of Hcp was measured relative to wt + pvirG by densitometry, and shown are the mean and SEM of at least 4
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an FDA-approved drug, 5-FC has a well-established safety
and clinical use profile and is readily accessible in many
melioidosis-endemic locales. It exhibits excellent bioavailability
and near ubiquitous distribution in host compartments, including
cerebrospinal fluid (51). In Burkholderia, 5-FC acts as a prodrug
that requires conversion to 5-FU and FUMP for inhibitory ac-
tivity. This confers selectivity since human cells lack CodA and
cannot efficiently metabolize 5-FC (51). In contrast to suscepti-
ble fungi (55), the lack of a primary effect on growth and the lack
of dependence on thymidine phosphorylase or ribonucleotide
reductase (Fig. 5) suggest that lethal inhibition of RNA or DNA
synthesis are not of primary importance. Instead, our staging of
the effects of 5-FC in relation to the intracellular life cycle (Fig. 4
B–J), the observation that 5-FC suppresses Hcp5 secretion
in vitro (Fig. 4I), and the phenotypes of resistant mutants (Fig. 6;
see below) are consistent with the hypothesis that inhibition of
T6SS-5 activity is primarily responsible for the ability of 5-FC to
inhibit cell–cell spread. Effects on other requirements for in-
tracellular survival and replication may occur, but our results ar-
gue that they are not the primary point of inhibition in the assays
we employed.
In our in vitro and cell-based assays, 5-FC acts as an anti-
virulence agent (66, 67), and targeting virulence as opposed to
growth may be advantageous for several reasons. First, anti-
virulence agents are proposed to exert reduced selective pressure
for resistance, although this has been difficult to demonstrate
experimentally (66–68). Second, unlike conventional antibiotics
which target widely conserved and essential pathways, anti-
virulence agents typically target pathogen-specific virulence
pathways that are dispensable for growth and therefore may be
less likely to disrupt beneficial microbes. Moreover, the unique
mechanisms of action of antivirulence agents like 5-FC provide
opportunities for synergy when combined with established ther-
apies or promising leads such as BFX, which target growth.
Further efforts to develop 5-FC will focus in part on its use as an
adjunctive therapy to treat melioidosis.
Through chemical and targeted mutagenesis experiments, we
have identified 3 general pathways to 5-FC resistance. The first
and most efficient involves mutations in genes encoding cytosine
deaminase (codA) or uracil phosphoribosyltransferase (upp),
which are required for conversion of 5-FC prodrug to active
metabolites, and we anticipate that mutations in the codB
transporter locus would have a similar effect. Fluorinated py-
rimidines have also been found to exert antivirulence effects in
P. aeruginosa, and although the mechanism remains unclear,
disruptions in codA and upp were similarly found to confer re-
sistance (68, 69). A second pathway that leads to partial re-
sistance results from mutations in a region of chromosome II
that encodes putative regulatory factors such as IsrA and IsrB.
Although further study is required to understand their roles in
virulence, the intriguing observation that a transposon insertion
in isrA results in accelerated plaque development in the absence
of inhibitor suggests that IsrA plays a negative role in regulating
1 or more factors involved in intracellular spread. A third path-
way, which also confers partial resistance, involves inactivation of
a biosynthetic gene (thaP) required for production of thai-
landamide, a potent inhibitor of acetyl-coA carboxylase (AccA)-
dependent fatty acid synthesis (57, 58). How might the lack of
production of a polyketide antibiotic increase the efficiency of
cell–cell spread? An important clue comes from the observation
that in addition to inhibiting growth of competing bacteria (57,
58), thailandamide has cytotoxic activity against mammalian cells
(70). We speculate that partial disruption of host cell fatty acid
biosynthesis by intracellular bacteria could alter membrane
properties and decrease the efficiency of T6SS-5 dependent fu-
sion or compromise mechanisms that repair membrane damage
resulting from nonproductive deployment of the fusion ma-
chinery. In either case, eliminating thailandamide production
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Materials and Methods. (B) Flucytosine and BFX decreased bacterial loads in
the lung, liver, and spleen of mice infected with Bp 1026b (*P < 0.05). Organs
were harvested 48 h after infection, and bacterial burden was measured by
diluting and plating homogenized organs. Number of mice per group = 4.
(C) Flucytosine and BFX reduced inflammation and necrosis in the lung,
spleen, and liver tissue of infected mice. Shown are lung, spleen, and liver
sections from PBS-, 5-FC–, and BFX-treated mice harvested 48 h after in-
fection. PBS-treated mouse lung tissue showed extensive interstitial, peri-
vascular, and peribronchiolar inflammation (black arrows). Inflammation
was less prominent and more focal in 5-FC–treated mouse lungs (black ar-
row) and was absent in BFX-treated lungs. Splenic tissue from PBS-treated
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duced in 5-FC–treated mice and undetectable in BFX-treated mice. All error
bars represent the SEM. (Scale bars, 300 μm.)
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would be predicted to increase the efficiency of cell–cell spread
as measured by in vitro plaque assays.
Having identified pathways to 5-FC resistance in vitro, it is
important to consider their potential clinical relevance in re-
lation to the ecology and epidemiology of Bp. Human infections
invariably arise from environmental sources (4), and it seems
likely that mutations in genes required for pyrimidine salvage
(i.e., codA, codB, and upp) would be subject to negative selection
in nature. The effects of such mutations on Bp virulence in an-
imals are also unknown. Similarly, although disruption of isrA or
other potential regulatory loci may increase the efficiency of
intercellular spread in cell monolayers, further experiments will
be required to determine if this correlates with increased or at-
tenuated virulence in vivo. Given the importance of precise
control in bacterial–host interactions, we predict the latter pos-
sibility will be true. Finally, although thailandamide is produced
by Bt strains, the biosynthetic gene cluster is absent from Bp and
Bm genomes (71), making this pathway of lesser relevance for
treating melioidosis or glanders. Nonetheless, it is tempting to
speculate that inhibition of host cell fatty acid synthesis could
contribute to the relative avirulence of Bt compared to Bp and
Bm. Although our chemical mutagenesis screen was designed to
reveal the mechanism of inhibition by 5-FC, mutations that im-
plicate a specific molecular target were not identified. If 5-FC
ultimately targets a factor required for T6SS-5 apparatus as-
sembly, function, or deployment, it may be difficult or impossible
to generate mutations in a single step that eliminate inhibition
while preserving secretory and fusogenic activity, as dictated by
our selection protocol. Similarly, effects on regulatory factors or
levels of a small-molecule signal may be difficult to evade with-
out disrupting essential control circuits. Given the apparent
utility of 5-FC and the required role of T6SS-5 in pathogenesis, it
is clearly of interest to identify the molecular targets and
mechanisms responsible for inhibition.
A limitation of our study is that the primary screen was con-
ducted with the BSL-2 surrogate Bt for relative ease of manip-
ulation. As we later found, many of our primary hits had no
effect on Bp or Bm. Although Bt, Bp, and Bm utilize many
conserved virulence mechanisms, their genomes differ consid-
erably in size, metabolic gene content, and homology (71, 72).
Subtle differences in intercellular life cycles, drug uptake or re-
tention, or metabolic strategies of these species may have con-
tributed to the differential susceptibility observed in our study.
Although our screen was successful in identifying therapeutic
leads for Bp and/or Bm, a potentially superior but more chal-
lenging approach would have been to conduct the primary screen
using these Tier 1 pathogens under BSL-3 containment. Finally,
our study demonstrated the efficacy of identified hits in clinical
isolates; however, follow-on strain surveys will be required to
guide translation to the clinical setting, as Bp is known to be
genetically variable (10).
Cell-based phenotypic screens are a promising approach to
drug discovery for intracellular bacterial pathogens, as validated
hits will have a priori demonstrated the ability to traverse the
host cell plasma membrane and bacterial cell envelope. This is
especially advantageous for gram-negative pathogens, for which
the outer membrane remains a formidable barrier for drug de-
velopment (73). The high-throughput screen described here
demonstrates the feasibility of this approach to identify new
therapeutic leads for melioidosis and glanders.
Materials and Methods
Study Design. Compounds in the UCLA MSSR library (www.mssr.ucla.edu)
were plated and tested in vitro for the ability to inhibit intercellular spread
with the identities and order of compounds blinded to the experimenter.
Due to its scale and expense, the ∼220,000–small-molecule HT screen was
performed with each compound tested once in a single well. Small mole-
cules deemed as positive hits in initial screening were cherry-picked from the
larger library to form a small positive hit library. This hit library was used to
validate positive hits in 384-well format, with at least 3 technical and 2 bi-
ological replicates per compound. Downstream cell-based infection experi-
ments were performed with at least 3 technical and 2 biological replicates.
Compounds were prioritized for further study based on their activity profiles
and toxicity for mammalian cells. Two compounds, BFX and 5-FC, were se-
lected for mechanistic studies, and their therapeutic efficacy was measured
in vivo in a mouse model of melioidosis. Animal studies were approved by
the University of Florida Institutional Animal Care and Use Committee
(IACUC) under protocol #201609601. Animals were randomly assigned to
treatment groups, and therapeutic efficacy was determined on the basis of
mortality, organ bacterial loads, and histopathological findings. Sample sizes
for in vivo studies were determined using Lamorte’s power calculations and
were selected to minimize the number of animals needed to obtain statis-
tically significant results. The HT small-molecule screen, follow-up mecha-
nistic assays, HT resistance screen, WGS and bioinformatics approach, animal
experiments, and data analysis are described in detail in SI Appendix.
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